The SFV is an excellent conduit for vascular access, whether it is transposed or is part of a composite PTFE-SFV fistula. In this series, fistula infection was nonexistent, thrombosis rates were low, and clinical evidence of venous hypertension was minimal. The major impediment to unrestricted use of SFV in constructing AVFs is a high incidence of clinically significant postoperative ischemia requiring reoperation.

No abstract

Improved patient selection and selective intraoperative femoral vein tapering eliminated remedial procedures to correct ischemia in patients undergoing tFV access. Patency rates were excellent despite the liberal use of vein tapering. Transposed FV access should be considered for good risk individuals undergoing their first lower extremity access.

No abstract

AVFs demonstrate excellent long-term patency with minimal complications in pediatric HD patients, regardless of weight. Concerted efforts should be made to improve the incident use of AVFs in all pediatric patients with end-stage renal disease.